Award Data

DESCRIPTION (provided by applicant): Affomix would like to commercialize antibody chips to enable researchers to study the human proteome. Currently, researchers use gene chips as a surrogate means to estimate the concentration of the vast variety of pro teins in cells and tissues. But given the choice, most researchers would prefer to study the proteins directly because of the; i) poor correla ...

DESCRIPTION (provided by applicant): Schizophrenia affects approximately 3 million people in the US, and it is one of the leading causes of disability. Currently available drugs are only partially effective, particularly for the cognitive impairments that contribute to functional loss. A new investigational drug, BMD-101, has been shown to have neuroprotective, neurotrophic, cholinergic, and dopa ...

DESCRIPTION (provided by applicant): Among the most undesirable sequelae of chemo- and radiotherapies for the treatment of cancer are bone marrow hypoplasia and pancytopenia. These can further lead to immunodeficiency, bleeding and hypoxia significantly i mpacting the morbidity of cancer patients. The discovery of growth factors that regulate hematopoietic stem cells (HSC) proliferation led to th ...

DESCRIPTION (provided by applicant): This Phase I STTR is focused on testing the feasibility of developing a scalable, commercial health information system based on ClinfoTracker, an existing system developed in an academic setting. The proposed system can significantly impact the recognition, tracking and management of chronic diseases such as cancers. By tracking and managing activities and out ...

DESCRIPTION (provided by applicant): The long-term objective of this research is to develop a technology and eventually a minimally-invasive commercial system for image-guided photodynamic therapy for cancer. This is certainly in keeping with NCI's focus o n imaging in vivo for cancer screening, diagnosis, progression, image-guide therapy, treatment monitoring, and recurrence. In studies conducted ...

DESCRIPTION (provided by applicant): Close to 40% of US children are exposed to secondhand tobacco smoke (SHS) in homes and up to 50% in cars, compromising the health and lives of millions of children. More effective, inexpensive, and accessible interventi ons are needed that impact parents' and caregivers' willingness and ability to institute smoking restrictions. We propose the development of an ...

DESCRIPTION (provided by applicant): GcFree, Inc. is founded on recent discoveries and patents about a sialic acid called Neu5Gc, which is present in large amounts on the surface of cells of most animals, but not humans. Potentially immunogenic Neu5Gc from exogenous sources (e.g., animal- derived reagents used for making biotherapeutic products) are taken up by human cells and expressed on their ...

DESCRIPTION (provided by applicant): The overall objective of this Phase I study is to establish the technological merit and feasibility of our proposed approach to developing and then commercializing a pair of companion prognostics for newly diagnosed non - muscle invasive Ta T1 urothelial carcinoma (UC) of the bladder that accurately predicts the relative chances of tumor recurrence and progress ...

DESCRIPTION (provided by applicant): Introduction: Computational models of human joint mechanics have become common in musculoskeletal science. Although existing deterministic models have provided significant insight into musculoskeletal mechanics, they c annot explain some important phenomena. The discrepancy between model predictions and experimental observations can be resolved by treating mod ...

DESCRIPTION (provided by applicant): Patient-specific therapies targeted to the phenotype of individual tumors represent the future of cancer treatment. The prototypes for this type of therapy are Herceptin and Tamoxifen, which are only given to patients e xpressing a particular level of HER2 and estrogen receptor (ER), respectively. It is likely that dozens of such therapies will be developed for ...